The PD-1 and PD-L1 Monoclonal Antibody Market — growing from USD 35.1 billion in 2025 toward USD 65 billion by 2035 — is entering a new phase of its commercial lifecycle. The first decade was defined by landmark approvals and first-in-class data; the next decade will be shaped by geographic market penetration, biosimilar entry, indication expansion into earlier treatment lines, and...
จองคิวบริการ
NR tours
Youplay
NR shop
NR jobs
facebook th
